# SIMONE (NCT06963905)

> Saci Nivo Rela for TNBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06963905
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Yale University
- Conditions: Metastatic Triple-negative Breast Cancer
- Interventions: Relatlimab FDC + Nivolumab; Sacituzumab Govitecan (SG); Nivolumab
- Enrollment: 60
- Primary outcome: Incidence and severity of dose limiting toxicities in patients treated with sacituzumab govitecan combinations

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=simone-nct06963905